Perifosine is an oral Akt inhibitor, currently evaluated in phase III clinical trials, shown to inhibit Akt and mitogen-activated protein kinase (MAPK) phosphorylation in prostate PC3 cells, multiple myeloma, HCC, glioma cells and renal carcinoma [50-54]. The gene discussed is WNK2; the disease is central nervous system cancer.